These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 29465777)
1. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. Raghavendra A; Kalita-de Croft P; Vargas AC; Smart CE; Simpson PT; Saunus JM; Lakhani SR Histopathology; 2018 Jul; 73(1):68-80. PubMed ID: 29465777 [TBL] [Abstract][Full Text] [Related]
2. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy? Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381 [TBL] [Abstract][Full Text] [Related]
3. Expression of cancer/testis antigens in salivary gland carcinomas with reference to MAGE-A and NY-ESO-1 expression in adenoid cystic carcinoma. Beppu S; Ito Y; Fujii K; Saida K; Takino H; Masaki A; Murase T; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Ijichi K; Murakami S; Inagaki H Histopathology; 2017 Aug; 71(2):305-315. PubMed ID: 28370175 [TBL] [Abstract][Full Text] [Related]
4. High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Badovinac Črnjević T; Spagnoli G; Juretić A; Jakić-Razumović J; Podolski P; Šarić N Med Oncol; 2012 Sep; 29(3):1586-91. PubMed ID: 22116775 [TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigen expression in triple-negative breast cancer. Curigliano G; Viale G; Ghioni M; Jungbluth AA; Bagnardi V; Spagnoli GC; Neville AM; Nolè F; Rotmensz N; Goldhirsch A Ann Oncol; 2011 Jan; 22(1):98-103. PubMed ID: 20610479 [TBL] [Abstract][Full Text] [Related]
6. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis. Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G Oncology; 2015; 89(6):337-44. PubMed ID: 26413775 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145 [TBL] [Abstract][Full Text] [Related]
8. Expression of tumor-associated antigens in breast cancer subtypes. Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767 [TBL] [Abstract][Full Text] [Related]
9. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576 [TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Veit JA; Heine D; Thierauf J; Lennerz J; Shetty S; Schuler PJ; Whiteside T; Beutner D; Meyer M; Grünewald I; Ritter G; Gnjatic S; Sikora AG; Hoffmann TK; Laban S Head Neck; 2016 Jul; 38(7):1008-16. PubMed ID: 26874246 [TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer. Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258 [TBL] [Abstract][Full Text] [Related]
13. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Kim SH; Lee S; Lee CH; Lee MK; Kim YD; Shin DH; Choi KU; Kim JY; Park DY; Sol MY Lung; 2009; 187(6):401-11. PubMed ID: 19795170 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M Tumori; 2014; 100(1):60-8. PubMed ID: 24675493 [TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033 [TBL] [Abstract][Full Text] [Related]
16. Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets. Xiao J; Huang F; Li L; Zhang L; Xie L; Liu B J Cancer Res Clin Oncol; 2023 Nov; 149(16):15003-15011. PubMed ID: 37610673 [TBL] [Abstract][Full Text] [Related]
17. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas. Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456 [TBL] [Abstract][Full Text] [Related]
18. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695 [TBL] [Abstract][Full Text] [Related]
19. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. Kerkar SP; Wang ZF; Lasota J; Park T; Patel K; Groh E; Rosenberg SA; Miettinen MM J Immunother; 2016 May; 39(4):181-7. PubMed ID: 27070449 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma. Hashimoto K; Nishimura S; Ito T; Oka N; Kakinoki R; Akagi M Eur J Histochem; 2022 Jun; 66(3):. PubMed ID: 35736245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]